About NovaMed Pharmaceuticals
NovaMed Pharmaceuticals is a Healthcare company based in Shanghai (China) founded in 2005, and was acquired by SciClone Pharmaceuticals in April 2011. Therapeutics for oncology, cardiovascular, and CNS disorders are developed. NovaMed Pharmaceuticals has raised $18.8 million across 2 funding rounds from investors including Atlas Venture, SciClone Pharmaceuticals and Eight Roads Ventures. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.
Company details
NovaMed Pharmaceuticals was founded in 2005 and is headquartered in Shanghai, China. The company operates in the pharmaceutical sector, where therapeutics are developed for oncology, cardiovascular disease, central nervous system disorders, urology, and infections. Key products include the broad-spectrum anti-convulsant Depakine, the anti-hypertension ACE inhibitor Tritace, the hypnotic anti-insomnia drug Stilnox, and the interventional cardiology product Aggrastat. Operations focus on research and development in these therapeutic areas.
- Headquarters Shanghai, China
- Stage Acquired
- SectorsHealthcare
- Website novamed.com.cn
- Social LinkedIn
- Acquired by SciClone Pharmaceuticals (Apr 2011)
- Total Equity Funding$18.8M (USD)
in 2 rounds
- Latest Funding Round$13.8M (USD), Series B
Jan 2008
- InvestorsAtlas Venture
& 2 more
- Acquired bySciClone Pharmaceuticals
(Apr 2011)
Funding Insights of NovaMed Pharmaceuticals
NovaMed Pharmaceuticals has successfully raised a total of $18.8M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $13.8 million completed in January 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.8M
- Total Rounds 2
- Last Round Series B — $13.8M
- First Round $5M
(Jul 2007)
- Investors Count 2
All 2 funding rounds of NovaMed Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2008 | $13.8M | Series B | – | – | |
| Jul 2007 | $5M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in NovaMed Pharmaceuticals
NovaMed Pharmaceuticals has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Atlas Venture, SciClone Pharmaceuticals and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Specialty biopharma company that develops and commercializes specialist-oriented drugs | 1989 | sciclone.com | Shanghai, China |
Investor details for NovaMed Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NovaMed Pharmaceuticals
4 dated milestones of NovaMed Pharmaceuticals across 6 years, from founding to its latest funding, stage changes and deals.
- Founded NovaMed Pharmaceuticals is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series B, of $13.8M.
- Exit Acquired by SciClone Pharmaceuticals.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novamed Pharmaceuticals
Complete news archive for NovaMed Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NovaMed Pharmaceuticals
NovaMed Pharmaceuticals was founded in 2005 and raised its 1st funding round 2 years after it was founded.
NovaMed Pharmaceuticals is headquartered in Shanghai, China.
NovaMed Pharmaceuticals is a funded company, having raised a total of $18.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Jul 2007.
NovaMed Pharmaceuticals was founded in 2005 and is headquartered in Shanghai, China. The company operates in the pharmaceutical sector, where therapeutics are developed for oncology, cardiovascular disease, central nervous system disorders, urology, and infections. Key products include the broad-spectrum anti-convulsant Depakine, the anti-hypertension ACE inhibitor Tritace, the hypnotic anti-insomnia drug Stilnox, and the interventional cardiology product Aggrastat. Operations focus on research and development in these therapeutic areas.
NovaMed Pharmaceuticals has 3 investors. Key investors include Atlas Venture, SciClone Pharmaceuticals, and Eight Roads Ventures.
Yes. NovaMed Pharmaceuticals was acquired by SciClone Pharmaceuticals in April 2011.